Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

949 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, Lessells AM, Lucraft HH, Summerfield GP, Proctor SJ; Scotland And Newcastle Lymphoma Group. Taylor PR, et al. Leuk Lymphoma. 2006 Nov;47(11):2321-30. doi: 10.1080/10428190600881256. Leuk Lymphoma. 2006. PMID: 17107904 Clinical Trial.
Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).
Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, White J, Windebank K, Taylor PR; Northern Region Lymphoma Group. Proctor SJ, et al. Among authors: taylor pr. Ann Oncol. 2003;14 Suppl 1:i47-50. doi: 10.1093/annonc/mdg710. Ann Oncol. 2003. PMID: 12736232 Free article.
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III).
Proctor SJ, Mackie M, Dawson A, White J, Prescott RJ, Lucraft HL, Angus B, Jackson GH, Lennard AL, Hepplestone A, Taylor PR. Proctor SJ, et al. Among authors: taylor pr. Eur J Cancer. 2002 Apr;38(6):795-806. doi: 10.1016/s0959-8049(02)00006-0. Eur J Cancer. 2002. PMID: 11937314 Clinical Trial.
949 results